American Journal of Cardiology
Volume 99, Issue 7 , Pages 1013-1015 , 1 April 2007

The Things to Come of SHAPE: Cost and Effectiveness of Cardiovascular Prevention

  • George A. Diamond, MD

      Affiliations

    • Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California
    • David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
    • Corresponding Author InformationCorresponding author: Tel: 323-462-0600; fax: 323-467-7490.
    • Dr. Diamond is a member of the speakers— panels of Merck & Co., Inc, West Point, Pennsylvania; and Schering-Plough Corporation, Kenilworth, New Jersey.
    • ,
  • Sanjay Kaul, MD

      Affiliations

    • Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California
    • David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

Received 16 October 2006 ,Revised 30 October 2006 ,Accepted 30 October 2006.

References 

  1. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al SHAPE Task Force (From vulnerable plaque to vulnerable patient—part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report). Am J Cardiol. 2006;98:2H–15H
  2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (Final report). Circulation. 2002;106:3143–3421
  3. In:  Miller W,  Robinson LA,  Lawrence RS editor. Committee to Evaluate Measures of Health Benefits for Environmental, Health, and Safety Regulation (Valuing Health for Regulatory Cost-Effectiveness Analysis). Washington, District of Columbia: National Academies Press; 2006;
  4. Diamond GA, Kaul S, Shah PK. Screen testing: Cardiovascular prevention in asymptomatic diabetics. J Am Coll Cardiol. In press.
  5. Sackett DL, Haynes RB, Tugwell P. In: Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston, Massachusetts: Little, Brown; 1985;p. 144–155302–310
  6. Huron Valley Physicians Association. HVPA cost comparison: statins/statin combos. 2006;Available at: http://www.hvpa.com/hvpa_rx_drug_cost_tables_files/statin_cost_comparisons_0606upd.pdf. June. Accessed July 27, 2006.
  7. American Heart Association. Heart Disease and Stroke Statistics—2006 Update. Dallas, Texas: American Heart Association; 2006;
  8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  10. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–215
  11. In: Statistical Abstract of the United States (Table 116. Deaths—life years lost and mortality costs by age, sex, and cause: 2000 and 2002). Washington, District of Columbia: U.S. Department of Commerce; 2006;p. 92
  12. Sturm JW, Donnan GA, Dewey HM, Macdonell RA, Gilligan AK, Srikanth V, et al. Quality of life after stroke (The North East Melbourne Stroke Incidence Study (NEMESIS)). Stroke. 2004;35:2340–2345
  13. Tsevat J, Goldman L, Soukup JR, Lamas GA, Conners KF, Chapin CC, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:160–165
  14. Garber A. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood). 2004;(suppl):W4-284–W4-289
  15. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events (The St. Francis Heart Study). J Am Coll Cardiol. 2005;46:158–165
  16. Hayward RA, Hofer TP, Vijan S. Lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145:520–530
  17. Kopjar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol. 2003;92:1106–1108
  18. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RMC. Long term persistence with statin treatment in daily medical practice. Heart. 2004;90:1065–1066
  19. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther. 2005;27:1639–1646
  20. Campione JR, Sleath B, Biddle AK, Weinberger M. The influence of physicians— guideline compliance on patients— statin adherence: a retrospective cohort study. Am J Geriatr Pharmacother. 2005;3:229–239
  21. Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61:667–674
  22. Kalia NK, Miller LG, Nasir K, Blumenthal RS, Agrawal N, Budoff JM. Visualization coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis. 2006;185:394–399
  23. O—Malley PG, Feurstein IM, Taylor AJ. Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial. JAMA. 2003;289:2215–2223

PII: S0002-9149(06)02510-0

doi: 10.1016/j.amjcard.2006.10.070

American Journal of Cardiology
Volume 99, Issue 7 , Pages 1013-1015 , 1 April 2007

Article Tools